Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography–Tandem Mass Spectrometry
Main Authors: | María del Mar Maldonado, Gabriela Rosado-González, Joseph Bloom, Jorge Duconge, Jean F. Ruiz-Calderón, Eliud Hernández-O’Farrill, Cornelis Vlaar, José F. Rodríguez-Orengo, Suranganie Dharmawardhane |
---|---|
Format: | Article |
Language: | English |
Published: |
American Chemical Society
2019-10-01
|
Series: | ACS Omega |
Online Access: | https://doi.org/10.1021/acsomega.9b01641 |
Similar Items
-
Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer
by: Luis E. Velázquez-Vega, et al.
Published: (2024-06-01) -
Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
by: Javier Reig-López, et al.
Published: (2020-10-01) -
Targeting Rac and Cdc42 GEFs in Metastatic Cancer
by: Maria del Mar Maldonado, et al.
Published: (2020-04-01) -
Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models
by: Anamaris Torres-Sanchez, et al.
Published: (2023-06-01) -
Estrogen and Resveratrol Regulate Rac and Cdc42 Signaling to the Actin Cytoskeleton of Metastatic Breast Cancer Cells
by: Nicolas G. Azios, et al.
Published: (2007-02-01)